AZD6482

For research use only.

Catalog No.S1462 Synonyms: KIN-193

16 publications

AZD6482 Chemical Structure

Molecular Weight(MW): 408.45

AZD6482 is a PI3Kβ inhibitor with IC50 of 10 nM, 8-, 87- and 109-fold more selective to PI3Kβ than PI3Kδ, PI3Kα and PI3Kγ in cell-free assays. Phase 1.

Size Price Stock Quantity  
USD 170 In stock
USD 320 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's AZD6482 has been cited by 16 publications

4 Customer Reviews

  • Cells treated with either control or INPP4B siRNA and following a 1-hour treatment with either DMSO or 1 mmol/L inhibitor; pPRAS40T246 and total PRAS40 were run on a separate blot for which the bottom Ku-86 panel is the loading control(pan-PI3Ki: GDC-0941, PI3K-ai: BYL719,PI3K-bi: AZD6482)

    Mol Cancer Res, 2017, 15(6):765-775. AZD6482 purchased from Selleck.

  • Dose response curve of compound on melanoma cell lines.  Compound was dissolved in DMSO, added in a 5-fold dilution series, starting with 10 μM, and incubated for 72 hours.  Fluorescence was measured after 8 hours incubation in resazurin.  Data was normalized to DMSO (maximal viability) and Doxorubicin (minimum viability).

    One customer. AZD6482 purchased from Selleck.

  • After starved in serum-free medium for 24h,A549 cells incubated with the indicated concentrations of AZD6482 for 3h,followed by 20-minute stimolation of 100ng/ml EGF.

    Dr. Zhang of Tianjin Medical University. AZD6482 purchased from Selleck.

  • Collagen-embedded melanoma spheroids were treated for 72 h with SGI-1776 [5 μM] or AZD6482 [10 μM] as single agents or in combination before staining for live (green) and dead (red) cells. Experiments were conducted in triplicate and representative images are shown. Scale bar represents 150 microns.

    Oncotarget, 2016, 7(34):54897-54912. AZD6482 purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description AZD6482 is a PI3Kβ inhibitor with IC50 of 10 nM, 8-, 87- and 109-fold more selective to PI3Kβ than PI3Kδ, PI3Kα and PI3Kγ in cell-free assays. Phase 1.
Targets
PI3Kβ [1]
(Cell-free assay)
PI3Kδ [1]
(Cell-free assay)
DNA-PK [1]
(Cell-free assay)
PI3Kα [1]
(Cell-free assay)
10 nM 80 nM 420 nM 870 nM
In vitro

AZD6482 also inhibits PI3Kα, γ, and δ, with IC50 of 80 nM to 1.09 μM, which are significantly lower than its (+)-enantiomer (S-form). AZD6482 is an antiplatelet agent; it blocks platelet activation adhesion/aggregation and promotes platelet disaggregation in assay of washed platelet aggregation (WPA), with an IC50 value of 6 nM. Furthermore, by targeting PI3Kβ, AZD6482 specifically inhibits thrombosis without interfering with normal haemostasis. Therefore, AZD6482 is used as an anti-thrombotic drug for the prophylaxis of thrombotic disorders. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human RXF393 cell MkXNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2H2ZmlvcGmkaYTpc44hd2ZiaIXtZY4hWliIM{mzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4xOTF3NDFOwG0> NFjMT45USU6JRWK=
human SW982 cell NVTYfIRkT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MV3Jcohq[mm2aX;uJI9nKGi3bXHuJHNYQTh{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6wN|U5PCEQvF2= NH;4TpFUSU6JRWK=
human MAD-MB-468 cells MmSxSpVv[3Srb36gZZN{[Xl? M3XKWmlvcGmkaYTpc44hd2ZiUFmzT4JmfGFiaX6gbJVu[W5iTVHEMW1DNTR4ODDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKFOnckS3N{BCc3RicHjvd5Bpd3K7bHH0bY9vKGK7IHPlcIx2dGG{IIDveIVv[3liYYPzZZktKEmFNUC9NE4xPCEQvF2= NIL1SI4zPDl7Mki3OC=>
human KURAMOCHI cell NV7Td3JZT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlTxTY5pcWKrdHnvckBw\iCqdX3hckBMXVKDTV;DTGkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjFyNUGg{txO MofXV2FPT0WU
human A498 cell NW\3SVkzT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWC2So1sUW6qaXLpeIlwdiCxZjDoeY1idiCDNEm4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOTd7NTFOwG0> MV;TRW5ITVJ?
human YT cell NX:xNYtKT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGK2XpNKdmirYnn0bY9vKG:oIHj1cYFvKFmWIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xNlA3PiEQvF2= NYHH[mhzW0GQR1XS
human VMRC-RCZ cell MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVnJcohq[mm2aX;uJI9nKGi3bXHuJHZOWkNvUlPaJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yPDh7ODFOwG0> M3jBbHNCVkeHUh?=
human MDA-MB-415 cell NYnPfGp6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIS1RVNKdmirYnn0bY9vKG:oIHj1cYFvKE2GQT3NRk01OTViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkG2O|MzKM7:TR?= M321XXNCVkeHUh?=
human J82 cell NXiwbXNpT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mn:zTY5pcWKrdHnvckBw\iCqdX3hckBLQDJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkS3O|c6KM7:TR?= MoDlV2FPT0WU
human SW1710 cell NYX1UXVVT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXTJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTdzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOVI6OiEQvF2= Mn3ZV2FPT0WU
human T47D cell NFXTSZdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIn1SIFKdmirYnn0bY9vKG:oIHj1cYFvKFR2N1SgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlU{OjdizszN M4H0d3NCVkeHUh?=
human SU-DHL-1 cell NVLTRWdGT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYPJcohq[mm2aX;uJI9nKGi3bXHuJHNWNUSKTD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE42PjhzMzFOwG0> NWX3Z4t3W0GQR1XS
human BT-20 cell MnS5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NX60ZYEyUW6qaXLpeIlwdiCxZjDoeY1idiCEVD2yNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPTl{MkKg{txO NWXrXXFsW0GQR1XS
human OS-RC-2 cell M2nuTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NX7DOm5PUW6qaXLpeIlwdiCxZjDoeY1idiCRUz3SR{0zKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC54MkO4PEDPxE1? NXz5VJRTW0GQR1XS
human RPMI-6666 cell NIDmR4JIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWPJcohq[mm2aX;uJI9nKGi3bXHuJHJRVUlvNk[2OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPjR|N{mg{txO MXLTRW5ITVJ?
human OVCAR-3 cell MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYSwclhrUW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk0{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC54N{m0OkDPxE1? NUnsR2hqW0GQR1XS
human NALM-6 cell NF[3VVRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1;ab2lvcGmkaYTpc44hd2ZiaIXtZY4hVkGOTT22JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44ODR4NTFOwG0> NIjnXXlUSU6JRWK=
human RS4-11 cell NUX4WWEyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MoTrTY5pcWKrdHnvckBw\iCqdX3hckBTWzRvMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlc{QDB4IN88US=> MXPTRW5ITVJ?
human SK-MES-1 cell MmfhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWDJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU2HUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44QDl4NzFOwG0> NIrEO|JUSU6JRWK=
human ES7 cell Mk\PS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mnu5TY5pcWKrdHnvckBw\iCqdX3hckBGWzdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkixNlg3KM7:TR?= NIDuUnFUSU6JRWK=
human NCI-H2342 cell MYrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{HGVGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyN|QzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC56NEK5OEDPxE1? NF31PZNUSU6JRWK=
human SCC-9 cell MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MoPSTY5pcWKrdHnvckBw\iCqdX3hckBUS0NvOTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPFU4PyEQvF2= NYLMZYZXW0GQR1XS
human EW-7 cell MlfsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHPsTnJKdmirYnn0bY9vKG:oIHj1cYFvKEWZLUegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlg3OzV4IN88US=> NXHyVVJ2W0GQR1XS
human HH cell NYHIfGsxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXyybGhoUW6qaXLpeIlwdiCxZjDoeY1idiCKSDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPVYzOjJizszN M4n2NnNCVkeHUh?=
human A427 cell MnHvS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MX7Jcohq[mm2aX;uJI9nKGi3bXHuJGE1OjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkm5OVA2KM7:TR?= MmTqV2FPT0WU
human Daudi cell NUDvWJVMT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NWT4TodEUW6qaXLpeIlwdiCxZjDoeY1idiCGYYXkbUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvODZ6OEig{txO MWnTRW5ITVJ?
human P30-OHK cell MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2XRO2lvcGmkaYTpc44hd2ZiaIXtZY4hWDNyLV;IT{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvODdzM{ig{txO M4\1dXNCVkeHUh?=
human HGC-27 cell NV7seYhNT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHLQN4FKdmirYnn0bY9vKG:oIHj1cYFvKEiJQz2yO{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F697zOIFnDOVA:OS5zOEG2JO69VQ>? MnXUV2FPT0WU
human CAMA-1 cell NEfINlVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MofWTY5pcWKrdHnvckBw\iCqdX3hckBESU2DLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlIxODFizszN NYPGU21wW0GQR1XS
human SK-OV-3 cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3PSVGlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvT2[tN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOjB2NESg{txO NEPFNVVUSU6JRWK=
human NCI-H1048 cell NITUNY9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NU\NfmJsUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFExPDhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkKyOVc6KM7:TR?= NFnme4FUSU6JRWK=
human MEL-HO cell MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{XxOGlvcGmkaYTpc44hd2ZiaIXtZY4hVUWOLVjPJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4zPDJ|ODFOwG0> NGHqbYhUSU6JRWK=
human NKM-1 cell NUPrdGQ3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVewPI1wUW6qaXLpeIlwdiCxZjDoeY1idiCQS12tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOjh4M{[g{txO MX3TRW5ITVJ?
human NCI-H650 cel NHLy[3FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGXzW4ZKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOlUxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5|MEC3OkDPxE1? NXK1S3FrW0GQR1XS
human HAL-01 cell NXvsPHdIT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUTJcohq[mm2aX;uJI9nKGi3bXHuJGhCVC1yMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuN|AyPzVizszN MnzLV2FPT0WU
human 786-0 cell MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn7yTY5pcWKrdHnvckBw\iCqdX3hckA4QDZvMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuN|EzQDNizszN M{XYenNCVkeHUh?=
human GI-1 cell NGXEOFdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkjyTY5pcWKrdHnvckBw\iCqdX3hckBIUS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT6zNVgxQCEQvF2= Mn7mV2FPT0WU
human Becker cell NVuwXG1XT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFTGUZFKdmirYnn0bY9vKG:oIHj1cYFvKEKnY3vldkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvOzZ|MUWg{txO NUnI[VJUW0GQR1XS
human CCF-STTG1 cell NILpWYRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHnrNHhKdmirYnn0bY9vKG:oIHj1cYFvKEOFRj3TWHRIOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTFwNEK1NlUh|ryP NFz3dFlUSU6JRWK=
human MC116 cell M4nYXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NUjqOFNYUW6qaXLpeIlwdiCxZjDoeY1idiCPQ{GxOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPDZzMkKg{txO MofkV2FPT0WU
human MDA-MB-468 cell NFfHemNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGHJcpdKdmirYnn0bY9vKG:oIHj1cYFvKE2GQT3NRk01PjhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkWzO|M3KM7:TR?= MnjyV2FPT0WU
human NB12 cell MYTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVTtVIJ{UW6qaXLpeIlwdiCxZjDoeY1idiCQQkGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU42PDh2MjFOwG0> NHyyXFRUSU6JRWK=
human LXF-289 cell NYn1TmltT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXfJcohq[mm2aX;uJI9nKGi3bXHuJGxZTi1{OEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlU2OTB2IN88US=> MWnTRW5ITVJ?
human MFE-296 cell M4S4TWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXm0V3U5UW6qaXLpeIlwdiCxZjDoeY1idiCPRlWtNlk3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS53NkizOkDPxE1? MWDTRW5ITVJ?
human SNU-423 cell M3;OPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3;4SmlvcGmkaYTpc44hd2ZiaIXtZY4hW06XLUSyN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEvPTdzOUKg{txO NHXMb5FUSU6JRWK=
human NCI-H2291 cell MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M4PzfGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNlkyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS53N{[xJO69VQ>? NWDmVIJ6W0GQR1XS
human OCUB-M cell MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NX\ibYZOUW6qaXLpeIlwdiCxZjDoeY1idiCRQ2XCMW0h[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjV6M{G0JO69VQ>? MVzTRW5ITVJ?
human KU812 cell MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mm[zTY5pcWKrdHnvckBw\iCqdX3hckBMXThzMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOVk3OjhizszN MVjTRW5ITVJ?
human HuO9 cell M1vCdmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYfHfGpCUW6qaXLpeIlwdiCxZjDoeY1idiCKdV:5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43OTJ6IN88US=> MVTTRW5ITVJ?
human 639-V cell NH7NVIJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEnPO2FKdmirYnn0bY9vKG:oIHj1cYFvKDZ|OT3WJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43OzF2NDFOwG0> MYHTRW5ITVJ?
human HCC70 cell M{LicGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoHkTY5pcWKrdHnvckBw\iCqdX3hckBJS0N5MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuOlYyPDZizszN NGXTNXdUSU6JRWK=
human SNB75 cell M4jifmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGe4OHpKdmirYnn0bY9vKG:oIHj1cYFvKFOQQke1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU43PjVyODFOwG0> NXPQN3RxW0GQR1XS
human D-336MG cell MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MV;Jcohq[mm2aX;uJI9nKGi3bXHuJGQuOzN4TVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlY3QDhizszN NYP0SGFQW0GQR1XS
human LoVo cell NEXuT|FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlrZTY5pcWKrdHnvckBw\iCqdX3hckBNd1[xIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT63N|gzPSEQvF2= MYfTRW5ITVJ?
human EB2 cell Ml\lS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXXC[mlrUW6qaXLpeIlwdiCxZjDoeY1idiCHQkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlc2ODF7IN88US=> NXvLS2VSW0GQR1XS
human HSC-2 cell NIDicGxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYjJcohq[mm2aX;uJI9nKGi3bXHuJGhUSy1{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT63OVczPyEQvF2= M2rsOXNCVkeHUh?=
human D-542MG cell Mn;kS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MXTJcohq[mm2aX;uJI9nKGi3bXHuJGQuPTR{TVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlg2ODd5IN88US=> NGDCRpVUSU6JRWK=
human COLO-684 cell M1ywcGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Ml\rTY5pcWKrdHnvckBw\iCqdX3hckBEV0yRLU[4OEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvOjByM{Kg{txO NGLNTFdUSU6JRWK=
human GDM-1 cell M{XaXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVj3NVBpUW6qaXLpeIlwdiCxZjDoeY1idiCJRF2tNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvOjR{ME[g{txO M{PTOHNCVkeHUh?=
human SW1088 cell M365U2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWnJcohq[mm2aX;uJI9nKGi3bXHuJHNYOTB6ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuOFgyPDNizszN NWXsfmZCW0GQR1XS
human SF295 cell MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXXJcohq[mm2aX;uJI9nKGi3bXHuJHNHOjl3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mj63Olk2PSEQvF2= M3\kfXNCVkeHUh?=
human NCI-H2030 cell MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEXyVXZKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlA{OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJwOUCyPFgh|ryP MUHTRW5ITVJ?
human NCI-H1755 cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXXJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUe1OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvOjdyNkOg{txO M2TC[3NCVkeHUh?=
human MDA-MB-361 cell M4jvcGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{\FSGlvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVM3OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTNwNUK3NFkh|ryP NIH0d|BUSU6JRWK=

... Click to View More Cell Line Experimental Data

Protocol

Kinase Assay:[1]
- Collapse

Assay of PI3K enzyme inhibition:

The inhibition of PI3Kβ, PI3Kα, PI3Kγ, and PI3Kδ is evaluated in an AlphaScreen based enzyme activity assay using human recombinant enzymes. The assay measures PI3K-mediated conversion of PIP2 to PIP3. Biotinylated PIP3, a GST-tagged pleckstrin homology (PH) domain and the two AlphaScreen beads form a complex that elicits a signal upon laser excitation at 680 nm. The PIP3 formed in the enzyme reaction competes with the biotinylated PIP3 for binding to the PH domain thus reducing the signal with increasing enzyme product. The AZD6482 is dissolved in DMSO and added to 384 well plates. PBKβ, PBKα, PBKγ, or PBKδ is added in a Tris buffer (50 mM Tris pH 7.6, 0.05% CHAPS, 5 mM DTT, and 24 mM MgCl2) and allowed to preincubate with AZD6482 for 20 minutes prior to the addition of substrate solution containing PIP2 and ATP. The enzyme reaction is stopped after 20 minutes by addition of stop solution containing EDTA and biotin-PIP3, followed by addition of detection solution containing GST-grpl PH and AlphaScreen beads. Plates are left for a minimum of 5 hours in the dark prior to analysis. The final concentration of DMSO, ATP and PIP2 in the assay are, 0.8%, 4 μM, and 40 μM, respectively. IC50 values are calculated according to the equation, y = {a+[(b-a)/(l+(x/IC50)s)]}, where y = % inhibition; a = 0%; b = 100%; s = the slope of the concentration-response curve; x = AZD6482 concentration.
Cell Research:[1]
- Collapse
  • Cell lines: Human platelet pellet
  • Concentrations: 0–60 nM, dissolved in DMSO
  • Incubation Time: 5 min
  • Method: For assay of washed platelet aggregation (WPA), the platelet pellets are isolated from human blood and re-suspended to 2 × 1015/L in Tyrodes buffer (TB) containing 1 μM hirudin and 0.02 U/mL apyrase. Then, the platelet suspension is left to rest at room temperature for 30 min. Just prior to time for assay, CaCl2 is added to a final concentration of 2 mM. AZD6482, dissolved in DMSO, is added to a 96-well plate prior to the addition of the washed platelet suspension. The platelet suspension is preincubated with AZD6482 for 5 min. Light absorption at 650 nm is recorded before and after a 5 min plate shake and referred to as recording 0 (R0) and Rl. A mouse anti-human CD9 antibody is added (at a donor specific concentration) to each well prior to next 10 min plate shake and light absorption recording; R2. For data analysis, light absorbance in wells with TB are subtracted from all readings before percent aggregation is calculated according the formula: [(R1-R2)/R1] × 100 = % aggregation. Spontaneous aggregation or pro-aggregatory effect of the inhibitor is evaluated by the same formula, [(R0-Rl)/R0] × 100 = % aggregation. IC50 values are calculated according to the equation, y = {a+[(b-a)/(l+(x/IC50)s)]}, where y = % inhibition; a = 0%; b = 100%; s = the slope of the concentration-response curve; x = AZD6482 concentration.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 82 mg/mL (200.75 mM)
Ethanol 10 mg/mL (24.48 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 408.45
Formula

C22H24N4O4

CAS No. 1173900-33-8
Storage powder
in solvent
Synonyms KIN-193
Smiles CC(NC1=CC=CC=C1C(O)=O)C2=CC(=CN3C(=O)C=C(N=C23)N4CCOCC4)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy AZD6482 | AZD6482 supplier | purchase AZD6482 | AZD6482 cost | AZD6482 manufacturer | order AZD6482 | AZD6482 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID